Date:9/6/2012

rayTomoAdjustmentsCombinedLoss From Operations$  (4,468)$  (35,585)$
29,788$
(10,265)$
(7,438)$ (69,251)$
34,929$  (41,760)Other Income (Expense)27237-2642,3413,951-6,292Provision For (Benefit from) Income
Taxes(35)105-701,0111,034-2,045Noncontrolling Interest-(1,574)-(1,574)-(6,967)-(6,967)Net Loss Attributable to Stockholders$  (4,406)$  (33,879)$
29,788$
(8,497)$
(6,108)$ (59,367)$
34,929$  (30,546)Net Loss Per Share - Basic and Diluted$
(0.07)$
(0.12)$
(0.10)$
(0.44)Weighted Average Common Shares
outstanding - Basic and Diluted62,45171,564(H)60,08569,198 (H) (H)

Represents weighted average common shares outstanding used to compute our basic and diluted net loss per share as disclosed in our Form 10-K for the twelve months ended June 30, 2011, adjusted to reflect the acquisition of TomoTherapy as if it occurred on July 1, 2010. 

 

'/>"/>

SOURCE Accuray Incorporated Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
2. Accuray to Acquire Morphormics, Inc.
3. Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
4. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
5. Accuray Rolls Out Comprehensive Customer Service Program in Japan
6. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
7. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
8. Accuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
9. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
10. Accuray Announces Results for Third Quarter Fiscal 2012
11. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer